NPS-1034

a protein kinase inhibitor that acts on MET and AXL; structure in first source

Networked: 3 relevant articles (2 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 06/01/2014 - "Together, these results suggest that NPS-1034 can be used as a potent therapeutic agent for human malignancies bearing MET point mutations or expressing activated MET." 06/01/2014 - "NPS-1034 inhibited the proliferation of cells expressing activated MET and promoted the regression of tumors formed from such cells in a mouse xenograft model through anti-angiogenic and pro-apoptotic actions. "
2.	Lung Neoplasms (Lung Cancer) 01/01/2014 - "MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation."
3.	Testicular Neoplasms (Testicular Cancer) 02/27/2022 - "However, no study on treating testicular cancer (TC) cell lines with NPS-1034 has been established. " 02/27/2022 - "NPS-1034 Induce Cell Death with Suppression of TNFR1/NF-κB Signaling in Testicular Cancer."

1.	Phosphotransferases (Kinase)
2.	Type I Tumor Necrosis Factor Receptors